A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
Clinical trial NCT02516527 · COMPLETED
Trial details
- NCT number
- NCT02516527
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-16
- Primary completion
- 2018-09-20
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.